ReviewClinical ophthalmology (Auckland, N.Z.)2018
Management of chronic ocular sarcoidosis: challenges and solutions.
Review in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Diagnostic Role of Multimodal Imaging in Optic Disc Diseases.Diagnostics (Basel, Switzerland) · 2026Review
- Unilateral Panuveitis Secondary to Toxoplasmosis in an Immunocompromised Patient: A Case Report.Cureus · 2026Article
- Nodular conjunctivitis as a novel ocular manifestation of canine sterile granuloma/pyogranuloma syndrome.BMC veterinary research · 2026Article
- Early Optic Nerve Symptoms in Neurosarcoidosis: A Clinical Case Review.Clinical case reports · 2025Article
- Clinical and Ophthalmological Characteristics and Therapeutic Management of Patients With Sarcoidosis.Cureus · 2025Article
- Article
- Fatty acid degradation-related gene signatures as biomarkers for ocular sarcoidosis.Scientific reports · 2025Article
- Development and validation of potential molecular subtypes and signatures of ocular sarcoidosis based on autophagy-related gene analysis.Open medicine (Warsaw, Poland) · 2025Article
- Sarcoidosis: a general overview.Advances in rheumatology (London, England) · 2024Review
- A Case of Unilateral Vision Loss Due to Optic Disc Infiltration by Sarcoidosis.Journal of general internal medicine · 2024Article
- Autoimmune Disease-Related Dry Eye Diseases and Their Placement Under the Revised Classification Systems: An Update.Cureus · 2023Review
- Retinitis Pigmentosa Masquerades: Case Series and Review of the Literature.Journal of clinical medicine · 2023Article
- A case of oculocutaneous sarcoidosis.American journal of ophthalmology case reports · 2023Article
- Choroidal sarcoid granuloma: a case report and review of the literature.Journal of ophthalmic inflammation and infection · 2022Review
- Sarcoid Uveitis: An Intriguing Challenger.Medicina (Kaunas, Lithuania) · 2022Review
- A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.Pulmonary therapy · 2021Review
- Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update.European journal of clinical investigation · 2021Review
- Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements.International ophthalmology · 2020Article
- Refractory Sarcoidosis: A Review.Therapeutics and clinical risk management · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis constitutes one of the leading causes of ocular inflammation. Chronic ocular sarcoidosis can affect any segment of the eye and its adnexa, producing a wide range of clinical manifestations and severity. If left untreated, permanent visual impairment or even blindness may ensue. Treatment approaches vary from topical therapy to systemic agents that induce immunosuppression to different levels according to disease severity.
objectiveTo review the published literature on the management options for chronic ocular sarcoidosis and provide a comprehensive list of available treatment strategies, including the newer biologics. SUMMARY: Ocular disease remains a challenging aspect of sarcoidosis and may even be the presenting sign of the disease. Prompt and effective therapy may reverse visual damage and prevent permanent loss of vision. Because of the complexity of the disease, a multidisciplinary approach is often required, with a view to addressing both the ocular and other systemic manifestations of sarcoidosis. Recent data suggest that achieving overall optimal systemic control is of paramount importance in controlling eye inflammation as well. Cytotoxic immunosuppressive agents for refractory chronic ocular disease, as well as biologic anti-TNFα therapies, have advanced the management of chronic disease and should be considered corticosteroid-sparing strategies before the onset of significant steroid-induced morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.